



REP 1001 vs HSV-1




FIG. 1a

REP2001 vs HSV-1




FIG. 1b

REP3007 vs HSV-1





FIG. 1c



**FIG. 2**

FIG. 3a




FIG. 3b




FIG. 3c




FIG. 3d




FIG. 3e




FIG. 3f







FIG. 3g






**FIG. 4**

### REP 2003 vs HSV-1




**FIG. 5a**

### REP 2009 vs HSV-1



**FIG. 5b**

### REP 2010 vs HSV-1



**FIG. 5c**

REP 2011 vs HSV-1




FIG. 5d

REP 2012 vs HSV-1




FIG. 5e

REP 2004 vs KOS




FIG. 5f

REP 2006 vs HSV-1




FIG. 5g

REP 2007 vs HSV-1




FIG. 5h

REP 2008 vs KOS





FIG. 5i





**FIG. 6**







FIG. 7




**FIG. 8a**




**FIG. 8b**




**FIG. 8c**



**FIG. 8d**



**FIG. 8e**



**FIG. 8f**

REP 2019 vs HSV-1




FIG. 8g

REP2020 vs HSV-1




FIG. 8h

REP 2121 vs HSV-1







FIG. 8i




**FIG. 9**



**FIG. 10**



**FIG. 11a**



**FIG. 11b**



### REP 2059 vs HSV-1




FIG. 11c

### REP 2060 vs HSV-1




FIG. 11d

### REP 1001 vs HSV-2




FIG. 12a

### REP2001 vs HSV-2




FIG. 12b

### REP3007 vs HSV-2





FIG. 12c



**FIG. 13**

FIG. 14a




FIG. 14b




FIG. 14c




FIG. 14d




FIG. 14e




FIG. 14f





FIG. 14g



Oligo size versus IC50 (HSV-2)




FIG. 15




FIG. 16a




FIG. 16b







FIG. 16c



**FIG. 17a**




**FIG. 17b**




**FIG. 17c**







**FIG. 17d**




**FIG. 17e**




**FIG. 17f**




**FIG. 17g**



**FIG. 17h**




**FIG. 17i**




**FIG. 18**

### REP 2004 vs HIV




**FIG. 19a**

### REP 2006 vs HIV




**FIG. 19b**

**REP 2004 vs MT4 lymphocytes**




**FIG. 19c**

**REP 2006 vs MT4 lymphocytes**



**FIG. 19d**

**Oligo size vs IC50 (HIV)**



**FIG. 20**

## Amprenavir (Agenerase™)

Patient: 02-136820-1C0-0-AMP — Ref.: CNDO-0000092947-039-AMP — EP: 54




FIG. 21a

## Indinavir (Crixivan™)

Patient: 02-136820-1C0-0-IDV — Ref.: CNDO-0000092947-039-IDV — EP: 540




FIG. 21b

## Lopinavir (Kaletra™)




FIG. 21c

## Saquinavir (Fortovase™)




FIG. 21d



## REP 2003

Patient: 02-136820-1C0-0-RP3 -- Ref.: CNDO-0000092947-039-RP3 -- EP: 541




FIG. 21e

## REP 2004

Patient 02-136820-1C0-0-RP4 -- Ref.: CNDO-0000092947-039-RP4 -- EP: 541




FIG. 21f

## REP 2006

Patient: 02-136820-1C0-0-RP6 -- Ref.: CNDO-0000092946-001-RP6 -- EP: 540




FIG. 21g

## REP 2007

Patient: 02-136820-1C0-0-RP7 -- Ref.: CNDO-0000092947-039-RP7 -- EP: 540





FIG. 21h

Drug	IC50 (uM)
REP 2003	4.01
REP 2004	0.065
REP 2006	0.014
REP 2007	0.015
Amprenavir	0.016
Indinavir	0.006
Lopinavir	0.004
Saquinavir	0.003

**FIG. 22a**



**FIG. 22b**

## Amprenavir (Agenerase™)

Patient: 02-136823-1C0-0-AMP -- Ref: CNDO-0000092947-039-AMP -- EP: 54




FIG. 23a

## Indinavir (Crixivan™)

Patient: 02-136823-1C0-0-IDV -- Ref: CNDO-0000092947-039-IDV -- EP: 540




FIG. 23b

## Lopinavir (Kaletra™)

Patient. 02-136823-1C0-0-LPV - Ref.. CNDO-0000092946-001-LPV - EP: 540




FIG. 23c

## Saquinavir (Fortovase™)

Patient 02-136823-1C0-0-SQV - Ref.. CNDO-0000092947-039-SQV -- EP 540




FIG. 23d

## REP 2003




FIG. 23e

## REP 2004




FIG. 23f

## REP 2006

Patient: 02-136823-1C0-0-RP6 -- Ref.: CNDO-0000092946-001-RP6 -- EP: 546




FIG. 23g

## REP 2007

Patient 02-136823-1C0-0-RP7 -- Ref.: CNDO-0000092947-039-RP7 -- EP: 546





FIG. 23h


Drug	IC50 (uM)		Fold change in IC50
	HIV-1 NL4-3	HIV-1 MRDC4	
REP 2003	4.01	3.69	0.92
REP 2004	0.065	0.046	0.71
REP 2006	0.014	0.014	1.00
REP 2007	0.015	0.013	0.87
Amprenavir	0.017	0.065	3.82
Indinavir	0.006	0.08	13.33
Lopinavir	0.004	0.096	24.00
Saquinavir	0.003	0.006	2.00

**FIG. 24**







**FIG. 25a**




**FIG. 25b**




**FIG. 25c**




**FIG. 25d**




**FIG. 25e**




**FIG. 25f**



**FIG. 25g**



**FIG. 25h**



**FIG. 26**

REP 2006 vs COX B2




FIG. 27a

REP 2006 vs LLC-MK2 cells




FIG. 27b

FP Serum Interaction test with PS-ODN randomers of increasing size  
baseline (unbound bait): 86mP




FIG. 28a

REP2006 delivery with DOTAP in 293A cells over time  
(50% serum)




FIG. 28b

Competition test with REP 2006 encapsulated with DOTAP




FIG. 28d

REP2006 delivery with cytofectin in 293A cells over time  
(50% serum)




FIG. 28c

Competition test with REP 2006 encapsulated with Cytofectin







FIG. 28e



**FIG. 29a**



**FIG. 29b**



**FIG. 29c**




FIG. 30a




FIG. 30b






FIG. 30c






**FIG. 31**

**Bait size vs p24 binding**



**FIG. 32a**

**Bait size vs gp41 binding**



**FIG. 32b**

Single and double stranded PS-ODNs can bind both HSV-1 and HIV-1  
lysates





FIG. 33



**FIG. 34**




FIG. 35a




FIG. 35b





FIG. 35c



**FIG. 36**

### SEQUENCE COMPOSITION VS ANTI-HSV EFFICACY




FIG. 37a

### Effect of sequence composition on efficiency against HSV-1




FIG. 37b